Many cheap biotech stocks jump quickly and return back to low prices that make many investors doubt in their stability but gamblers take risks and sometimes win enormous profits. However, Geron Corporation (NASDAQ: GERN) surges not so fast after the sharp fall in August 2018.
Since march GERN has been always rising based on weekly growing patterns. Between $0.96 and $1.93, there have been many shares sold and bought not so actively. However, many investors are holding the acquired shares.
On average of 3,339,189 shares, GERN could surge steadily without informing much about updates regarding new clinical studies unlike Moderna, Vaxart, CureVac, and iBio always practice.
Despite offering cheap shares in NASDAQ, Geron is too much overvalued by investors. Its actual value is multiple times less than the market cap. However, risk-averse investors may buy GERN because of the uptrending chart through the period of the pandemic.